Evidence map›Paper›PMID 38416732›Full record

ArticlePloS one2024

HIF-1 inhibition reverses opacity in a rat model of galactose-induced cataract.

Masaru Takashima, Masaya Nagaya, Yoshihiro Takamura, Masaru Inatani, Masaya Oki

Expression of concernOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Galactose-Induced Cataracts in Rats: A Machine Learning Analysis.International journal of medical sciences · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Masaru TakashimaDepartment of Industrial Creation Engineering, Graduate School of Engineering, University of Fukui, Fukui, Japan.
Masaya NagayaDepartment of Industrial Creation Engineering, Graduate School of Engineering, University of Fukui, Fukui, Japan.
Yoshihiro TakamuraDepartment of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Masaru InataniDepartment of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Masaya OkiDepartment of Industrial Creation Engineering, Graduate School of Engineering, University of Fukui, Fukui, Japan.ORCID 0000-0002-5563-0443
University of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cataract is an eye disease, in which the lens becomes opaque, causing vision loss and blindness. The detailed mechanism of cataract development has not been characterized, and effective drug therapies remain unavailable. Here, we investigated the effects of Hypoxia-inducible factor 1 (HIF-1) inhibitors using an ex vivo model, in which rat lenses were cultured in galactose-containing medium to induce opacity formation. We found that treatment with the HIF-1 inhibitors 2-Methoxyestradiol (2ME2), YC-1, and Bavachinin decreased lens opacity. Microarray analysis on 2ME2-treated samples, in which opacity was decreased, identified genes upregulated by galactose and downregulated by inhibitor treatment. Subsequent STRING analysis on genes that showed expression change by RT-qPCR identified two clusters. First cluster related to the cytoskeleton and epithelial-mesenchymal transition (EMT). Second cluster related to the oxidative stress, and apoptosis. ACTA2, a known marker for EMT, and TXNIP, a suppressor of cell proliferation and activator of apoptosis, were present in each cluster. Thus, suppression of EMT and apoptosis, as well as activation of cell proliferation, appear to underlie the decrease in lens opacity.

Indexed as

CataractLens, CrystallineAnimalsApoptosisCell Cycle ProteinsGalactoseHypoxia-Inducible Factor 1RatsCell Cycle ProteinsGalactoseHypoxia-Inducible Factor 1TXNIP protein, rat

Identifiers

PMID38416732
PMCPMC10901314
OpenAlexW4392230918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.